Mark N. Levine

47.5k total citations · 15 hit papers
320 papers, 31.4k citations indexed

About

Mark N. Levine is a scholar working on Oncology, Internal Medicine and Cancer Research. According to data from OpenAlex, Mark N. Levine has authored 320 papers receiving a total of 31.4k indexed citations (citations by other indexed papers that have themselves been cited), including 122 papers in Oncology, 80 papers in Internal Medicine and 65 papers in Cancer Research. Recurrent topics in Mark N. Levine's work include Venous Thromboembolism Diagnosis and Management (80 papers), Breast Cancer Treatment Studies (58 papers) and Cancer Treatment and Pharmacology (32 papers). Mark N. Levine is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (80 papers), Breast Cancer Treatment Studies (58 papers) and Cancer Treatment and Pharmacology (32 papers). Mark N. Levine collaborates with scholars based in Canada, United States and United Kingdom. Mark N. Levine's co-authors include Michael Gent, Agnes Lee, Jim A. Julian, Ajay K. Kakkar, Jack Hirsh, Clive Kearon, Frederick R. Rickles, Timothy J. Whelan, Kathleen I. Pritchard and Gary E. Raskob and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Mark N. Levine

315 papers receiving 30.1k citations

Hit Papers

Low-Molecular-Weight Heparin versus a Coumarin for the Pr... 1993 2026 2004 2015 2003 1995 2010 1996 2015 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
    2003 1.8k citations Agnes Lee, Mark N. Levine et al. profile →
  2. Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
    1995 1.7k citations Mark N. Levine et al. profile →
  3. Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
    2010 1.3k citations Timothy J. Whelan, Mark N. Levine et al. profile →
  4. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance.
    1996 989 citations Mark N. Levine et al. profile →
  5. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
    2015 968 citations Gary H. Lyman, Kari Bohlke et al. Journal of Clinical Oncology profile →
  6. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
    2019 934 citations Nigel S. Key, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  7. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
    2018 855 citations Annie Young, Andrea Marshall et al. Journal of Clinical Oncology profile →
  8. Hemorrhagic Complications of Anticoagulant Treatment
    2001 758 citations Mark N. Levine et al. CHEST Journal profile →
  9. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
    2007 723 citations Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  10. Venous Thromboembolism and Cancer: Risks and Outcomes
    2003 556 citations Agnes Lee, Mark N. Levine profile →
  11. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2013 544 citations Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  12. Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)
    2004 519 citations Ajay K. Kakkar, Mark N. Levine et al. Journal of Clinical Oncology profile →
  13. Vitamin C: the known and the unknown and Goldilocks
    2016 519 citations Mark N. Levine et al. profile →
  14. Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
    2008 517 citations Mark N. Levine et al. CHEST Journal profile →
  15. Influence of Cigarette Smoking on the Efficacy of Radiation Therapy in Head and Neck Cancer
    1993 457 citations Mark N. Levine et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark N. Levine Canada 84 12.3k 8.9k 6.7k 6.7k 4.3k 320 31.4k
Gary H. Lyman United States 104 8.7k 0.7× 6.1k 0.7× 24.9k 3.7× 7.7k 1.2× 6.8k 1.6× 602 48.3k
John A. Baron United States 105 2.6k 0.2× 3.4k 0.4× 12.3k 1.8× 9.7k 1.4× 3.7k 0.9× 520 39.8k
Frits R. Rosendaal Netherlands 101 15.7k 1.3× 11.3k 1.3× 1.1k 0.2× 6.6k 1.0× 898 0.2× 806 41.4k
Harry R. Büller Netherlands 92 24.6k 2.0× 18.6k 2.1× 1.3k 0.2× 8.6k 1.3× 658 0.2× 450 35.7k
Børge G. Nordestgaard Denmark 120 1.2k 0.1× 16.7k 1.9× 3.5k 0.5× 27.1k 4.1× 8.8k 2.0× 953 65.2k
Christopher P. Cannon United States 125 3.9k 0.3× 38.0k 4.3× 2.5k 0.4× 27.9k 4.2× 3.3k 0.8× 879 67.5k
Alan S. Go United States 93 4.9k 0.4× 25.3k 2.8× 1.2k 0.2× 5.6k 0.8× 470 0.1× 483 47.4k
Michael Gent Canada 90 16.1k 1.3× 20.2k 2.3× 775 0.1× 9.1k 1.4× 417 0.1× 230 34.9k
Gérald Simonneau France 116 6.6k 0.5× 30.4k 3.4× 1.7k 0.2× 7.9k 1.2× 1.2k 0.3× 567 58.8k
Samuel Z. Goldhaber United States 100 35.0k 2.8× 27.6k 3.1× 1.0k 0.2× 10.6k 1.6× 387 0.1× 614 47.4k

Countries citing papers authored by Mark N. Levine

Since Specialization
Citations

This map shows the geographic impact of Mark N. Levine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark N. Levine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark N. Levine more than expected).

Fields of papers citing papers by Mark N. Levine

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark N. Levine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark N. Levine. The network helps show where Mark N. Levine may publish in the future.

Co-authorship network of co-authors of Mark N. Levine

This figure shows the co-authorship network connecting the top 25 collaborators of Mark N. Levine. A scholar is included among the top collaborators of Mark N. Levine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark N. Levine. Mark N. Levine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Violet, Pierre-Christian, Hongbin Tu, Yu Wang, et al.. (2024). Altered RBC deformability in diabetes: clinical characteristics and RBC pathophysiology. Cardiovascular Diabetology. 23(1). 370–370. 5 indexed citations
3.
Rayner, Daniel, Anath C. Lionel, Nathan Cantor, et al.. (2024). Patient-Reported Outcome Measures in Cancer Care. JAMA Network Open. 7(8). e2424793–e2424793. 26 indexed citations
4.
Saha, Ashirbani, et al.. (2023). Measurement of adverse cosmesis in breast cancer: A deep learning approach. Expert Systems with Applications. 238. 122209–122209.
5.
Petch, Jeremy, Christopher Pettengell, Gregory R. Pond, et al.. (2023). Developing a Data and Analytics Platform to Enable a Breast Cancer Learning Health System at a Regional Cancer Center. JCO Clinical Cancer Informatics. 7(7). e2200182–e2200182. 5 indexed citations
6.
Chen, Ping, Yaohui Wang, Ruochen Dong, et al.. (2022). Pharmacokinetic Evaluation of Intravenous Vitamin C: A Classic Pharmacokinetic Study. Clinical Pharmacokinetics. 61(9). 1237–1249. 24 indexed citations
7.
Key, Nigel S., Alok A. Khorana, Nicole M. Kuderer, et al.. (2019). Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 38(5). 496–520. 934 indexed citations breakdown →
8.
Young, Annie, Andrea Marshall, Oliver Chapman, et al.. (2018). Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). Journal of Clinical Oncology. 36(20). 2017–2023. 855 indexed citations breakdown →
9.
Young, Annie, Andrea Marshall, Catherine St. Hill, et al.. (2017). Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial. Blood. 130. 625–625. 23 indexed citations
10.
Lyman, Gary H., Kari Bohlke, Alok A. Khorana, et al.. (2015). Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. Journal of Clinical Oncology. 33(6). 654–656. 968 indexed citations breakdown →
11.
Levine, Mark N., Jim A. Julian, Philippe L. Bédard, et al.. (2015). Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. Journal of Clinical Oncology. 34(10). 1065–1071. 60 indexed citations
12.
Olivotto, Ivo A., Timothy J. Whelan, Sameer Parpia, et al.. (2013). Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation Therapy. Journal of Clinical Oncology. 31(32). 4038–4045. 266 indexed citations
13.
Cheang, Maggie C.U., K. David Voduc, Dongsheng Tu, et al.. (2012). Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. Clinical Cancer Research. 18(8). 2402–2412. 105 indexed citations
14.
Pritchard, Kathleen I., Alison F. Munro, Frances P. O’Malley, et al.. (2011). Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Research and Treatment. 131(2). 541–551. 16 indexed citations
15.
Darling, Gail, Donna E. Maziak, Richard Inculet, et al.. (2011). Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial. Journal of Thoracic Oncology. 6(8). 1367–1372. 113 indexed citations
16.
Chan, Denise A., et al.. (2007). Hypoxia-inducible Factor-1α Stabilization in Nonhypoxic Conditions: Role of Oxidation and Intracellular Ascorbate Depletion. Molecular Biology of the Cell. 19(1). 86–94. 148 indexed citations
17.
Kakkar, Ajay K., Mark N. Levine, Paolo Prandoni, et al.. (2002). What is the role for antithrombotics in cancer care?. Cancer Treatment Reviews. 28(3). 157–159. 5 indexed citations
18.
Whelan, Timothy J., Amiram Gafni, Cathy Charles, & Mark N. Levine. (2000). Lessons learned from the Decision Board: a unique and evolving decision aid. Health Expectations. 3(1). 69–76. 30 indexed citations
19.
Coyle, Doug, Eva Grunfeld, Mark N. Levine, & W.K. Evans. (1997). PP15. Methods for conducting economic analysis of the long-term management of breast cancer: Description of two current Canadian studies. European Journal of Cancer. 33. S19–S20. 1 indexed citations
20.
Levine, Mark N., et al.. (1990). A New Short Infusion Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Venous Thromboembolic Disease. CHEST Journal. 97(4). 168S–171S. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gary H. Lyman Breakdown of academic impact, for papers by John A. Baron Breakdown of academic impact, for papers by Frits R. Rosendaal Breakdown of academic impact, for papers by Harry R. Büller Breakdown of academic impact, for papers by Børge G. Nordestgaard Breakdown of academic impact, for papers by Christopher P. Cannon Breakdown of academic impact, for papers by Alan S. Go Breakdown of academic impact, for papers by Michael Gent Breakdown of academic impact, for papers by Gérald Simonneau Breakdown of academic impact, for papers by Samuel Z. Goldhaber
Rankless by CCL
2026